US-based medical technology firm Origin has started treating patients in the Phase IIb-equivalent GENESIS trial of its nitric oxide (NO) technology for the treatment of chronic diabetic foot ulcers (DFUs).

The technology is the firm’s proprietary method being developed to produce and deliver plasma-generated NO in therapeutic quantities.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It involves a patented, portable device consisting of handheld, computer-guided system that produces nitrogen from ambient room air within a defined plasma stream. The generated NO is then delivered to the target treatment area.

“Plasma-generated nitric oxide has the potential to offer a new safe and effective therapy to close wounds actively, serving a large unmet need.”

The single-blinded 27-week GENESIS trial will demonstrate the healing and optimise the treatment regimen in approximately 100 patients across 15 clinical sites in the country.

Origin chairman and chief executive officer Michael Preston said: “Diabetes and consequential diabetic foot ulcers are a growing healthcare burden impacting millions of people.

“Plasma-generated nitric oxide has the potential to offer a new safe and effective therapy to close wounds actively, serving a large unmet need.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This marks another step forward in our mission to become the advanced therapy of choice for the treatment of DFUs.”

Following a two-week run-in period, patients will be randomised into one of four different dosing regimens or a standard of care (SOC) treatment arm to evalute efficacy and safety.

Patients will be treated over a period of 12 weeks and monitored for another 12 weeks after the treatment.

The firm intends to provide an update and initial readout of the interim results in the fourth quarter of this year.